Fonar Corp

Fonar Corp maintains a strong liquidity position with $56.33 million in cash and equivalents, representing 25.97% of total assets, and a current ratio of 8.45, well above the industry median of 2.1. The company's debt-to-equity ratio is effectively zero, indicating no long-term debt obligations, and its total liabilities amount to $44.30 million, which is 20.45% of total assets. The company's market capitalization of $123.64 million is significantly lower than its total equity of $172.61 million, suggesting a price-to-book ratio of 0.72, which is below the industry median of 1.2. Profitability metrics show Fonar Corp generating a net income of $8.33 million on $104.35 million in revenue, translating to a net margin of 7.98%, which is above the industry median of 5.2%. The company's return on equity (ROE) of 4.83% and return on assets (ROA) of 3.84% are below the industry medians of 8.1% and 5.7%, respectively, indicating room for improvement in asset utilization and capital efficiency. Gross profit of $42.91 million represents 41.13% of revenue, which is in line with the industry median of 40.5%. The company operates as a single business segment, with all revenue derived from the sale of MRI systems and related technologies. Geographically, Fonar Corp is primarily focused on the North American market, with no disclosed international revenue in the latest financials. This concentration exposes the company to regional economic and regulatory risks, particularly in the U.S. healthcare sector. Fonar Corp's revenue growth trajectory is modest, with no disclosed year-over-year growth in the latest period. The company's operating cash flow of $11.26 million and free cash flow of $11.36 million indicate strong cash generation, but capital expenditures of -$3.82 million suggest underinvestment in new capacity or technology. The price-to-earnings ratio of 14.84 is below the industry median of 18.5, suggesting the stock may be undervalued relative to earnings. Risk factors for Fonar Corp include regulatory changes in the U.S. healthcare sector, which could impact reimbursement rates for MRI services and, by extension, demand for the company's equipment. The company's low dilution risk is supported by no recent equity issuances and no shelf registration or ATM facilities disclosed in filings. However, the absence of long-term debt does not eliminate the risk of future financing needs, particularly if the company pursues expansion or R&D initiatives. Recent events include the company's continued focus on innovation in MRI technology, as highlighted in investor presentations and press releases. No material legal or regulatory actions were disclosed in the latest filings, and the company's ESG controversies score of 100.00 indicates no recent controversies. The governance pillar score of 3.68, however, suggests potential weaknesses in corporate governance practices.